Literature DB >> 23917308

Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases.

P Cormie1, R U Newton, N Spry, D Joseph, D R Taaffe, D A Galvão.   

Abstract

BACKGROUND: Due to concerns of fragility fracture, exercise is a perceived contraindication for prostate cancer patients with bone metastases. These patients experience significant functional impairment and muscle atrophy, which may lead to an increased likelihood of skeletal complicaTIOns (i.e., pathological fracture, bone pain) and/or falls. Safe resistance exercise prescription may counteract this effect. The aim of this feasibility trial was to determine the safety and efficacy of resistance exercise by prostate cancer survivors with bone metastatic disease.
METHODS: Twenty men with established bone metastases secondary to prostate cancer were randomly assigned to a 12-week resistance exercise program in which exercise prescription was based on the location of bone lesions (n=10) or usual care (n=10). Outcomes included safety and tolerance of the exercise program, physical function, physical activity level, body composition, fatigue, quality of life and psychological distress. Outcomes were compared between groups using analysis of covariance adjusted for baseline values.
RESULTS: Participants had significant disease load with 65% of participants presenting with two or more regions affected by bone metastases and an average Gleason score of 8.2±0.9. Five participants (exercise=2; usual care=3) did not complete the intervention, three of which were due to advancing disease (exercise=2; usual care=1). No adverse events or skeletal complications occurred during the supervised exercise sessions. The exercise program was well tolerated as evidenced by high attendance (83%) and compliance rates (93%), and the ability of the participants to exercise at an intensity within the target range for cancer survivors (rating of perceived exertion =13.8±1.5). The change in physical function (muscle strength ∼11%; submaximal aerobic exercise capacity ∼5% and ambulation ∼12%), physical activity level (∼24%) and lean mass (∼3%) differed significantly between groups following the intervention, with favorable changes in the exercise group compared with the usual care group. No significant between-group differences were observed for fatigue, quality of life or psychological distress.
CONCLUSIONS: This initial evidence involving a small sample size suggests that appropriately designed and supervised resistance exercise may be safe and well tolerated by prostate cancer patients with bone metastatic disease and can lead to improvements in physical function, physical activity levels and lean mass. Future trials involving larger sample sizes are required to expand these preliminary findings.

Entities:  

Mesh:

Year:  2013        PMID: 23917308     DOI: 10.1038/pcan.2013.22

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  65 in total

1.  Football training in men with prostate cancer undergoing androgen deprivation therapy: activity profile and short-term skeletal and postural balance adaptations.

Authors:  Jacob Uth; Therese Hornstrup; Jesper F Christensen; Karl B Christensen; Niklas R Jørgensen; Eva W Helge; Jakob F Schmidt; Klaus Brasso; Jørn W Helge; Markus D Jakobsen; Lars L Andersen; Mikael Rørth; Julie Midtgaard; Peter Krustrup
Journal:  Eur J Appl Physiol       Date:  2015-11-30       Impact factor: 3.078

2.  Understanding strength exercise intentions and behavior in hematologic cancer survivors: an analysis of the intention-behavior gap.

Authors:  James R Vallerand; Ryan E Rhodes; Gordon J Walker; Kerry S Courneya
Journal:  J Cancer Surviv       Date:  2016-04-06       Impact factor: 4.442

Review 3.  The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review.

Authors:  T Hasenoehrl; M Keilani; T Sedghi Komanadj; M Mickel; M Margreiter; M Marhold; R Crevenna
Journal:  Support Care Cancer       Date:  2015-05-24       Impact factor: 3.603

Review 4.  Diet and lifestyle considerations for patients with prostate cancer.

Authors:  Kyle B Zuniga; June M Chan; Charles J Ryan; Stacey A Kenfield
Journal:  Urol Oncol       Date:  2019-07-18       Impact factor: 3.498

5.  Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.

Authors:  Renée Bultijnck; Benedicte Deforche; Noëmi Borrey; Jörgen Van Bauwel; Maarten Lievens; Elke Rammant; Valérie Fonteyne; Karel Decaestecker; Adelheid Steyaert; Nicolaas Lumen; Piet Ost
Journal:  World J Urol       Date:  2020-02-01       Impact factor: 4.226

Review 6.  Systematic review of the multidimensional fatigue symptom inventory-short form.

Authors:  Kristine A Donovan; Kevin D Stein; Morgan Lee; Corinne R Leach; Onaedo Ilozumba; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2014-08-22       Impact factor: 3.603

7.  Exercise is more effective than health education in reducing fatigue in fatigued cancer survivors.

Authors:  Patricia Sheehan; Suzanne Denieffe; Niamh M Murphy; Michael Harrison
Journal:  Support Care Cancer       Date:  2020-02-04       Impact factor: 3.603

8.  Exercise for people with cancer: a clinical practice guideline.

Authors:  R Segal; C Zwaal; E Green; J R Tomasone; A Loblaw; T Petrella
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

9.  Physical activity and advanced cancer: the views of oncology and palliative care physicians in Ireland.

Authors:  G Sheill; E Guinan; L O Neill; D Hevey; J Hussey
Journal:  Ir J Med Sci       Date:  2017-08-31       Impact factor: 1.568

10.  Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.

Authors:  J Uth; T Hornstrup; J F Christensen; K B Christensen; N R Jørgensen; J F Schmidt; K Brasso; M D Jakobsen; E Sundstrup; L L Andersen; M Rørth; J Midtgaard; P Krustrup; E W Helge
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.